BIOFLOW III Asia Registry Orsiro Stent System

Inclusion Criteria: * Inclusion Criteria * Diabetes Mellitus: * Known Diabetic on Pharmacological treatment. * ACS NSTEMI with documented Hb A1c\> 7%, even if not on Pharmacological treatment for diabetes. * Patient has Symptomatic coronary artery disease * Target lesion must be a de novo lesion located in a native coronary artery with reference vessel diameter ≥2.25 mm \& ≤4.00 mm, lesion length ≤40 mm by visual estimate * Patient should be receiving up to 3 stents and up to 2 stents per artery. * Target lesion must be in a major coronary artery or branch with visually estimated stenosis ≥50% \& \<100% with TIMI flow≥1. * Subject provides signed informed consent for data release * Subject is geographically stable and willing to comply with protocol required follow ups * Subject is ≥ 18 years of age Exclusion Criteria: * Pregnant and/or breast-feeding females who intend to become pregnant during the period of the registry * Untreatable intolerance to aspirin, clopidogrel, ticlopidine, heparin or any other anticoagulation / antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media * Planned surgery within 6 months of PCI unless dual antiplatelet therapy will be maintained * Currently participating in another study and primary endpoint is not reached yet * If the subject has a high probability that a procedure other than predilatation, stent implantation and post dilatation will be required at time of index procedure for treatment of target vessel (e.g. atherectomy, cutting balloon or brachytherapy). * Patients admitted for treatment of Diabetic ketoacidosis ≥ 2 times in the past Six months (Brittle Diabetics).